Drug Pricing
Drug Pricing
Advancing Innovation and Access
We analyze the value that therapies bring to patients and develop novel payment models for rewarding innovation while restraining costs.
Featured Research
Most Medicare Beneficiaries May Pay More for Drugs Under the IRA
Part D plans are abruptly shifting more costs onto beneficiaries as they adjust to the IRA’s new cap on out-of-pocket spending.
Experts: Erin Trish
Related Subtopics
The Schaeffer Center is a nationally recognized leader on drug pricing research, with a particular focus on the economic system that distributes and pays for drugs. Our experts develop effective strategies for containing costs while rewarding new treatments based on the value they provide to patients.
Top Drug Pricing Stories View All
Perspective
Benchmarking Drug Prices To Inflation Overlooks What Truly Matters: Value
Featured Experts: William Padula
In The News View All
Associated Press
Padula comments on the difficulty of assessing the potential effects of the White House’s drug pricing deals
Featured Experts: William Padula
Medscape
Peters interviewed about how new GLP-1 guidelines and price reductions will affect patients
Featured Experts: Anne Peters
Modern Healthcare
Sood explains how newer, alternative PBMs often have business with legacy firms
Featured Experts: Neeraj Sood
KFF
Lakdawalla discusses recent developments in drug pricing policy on KFF webinar
Featured Experts: Darius Lakdawalla
Tradeoffs
Trish interviewed on rising Medicare drug plan costs and narrowing options
Featured Experts: Erin Trish
Featured White Paper
Mitigating the IRA’s Adverse Impacts on the Prescription Drug Market
Although the Inflation Reduction Act of 2022 (IRA) aimed to increase patient access to prescription drugs and decrease spending, researchers warn that it may have unintended negative impacts on patients in the long run. A Schaeffer Center white paper recommends three strategies to mitigate adverse impacts of the IRA.
Read the White PaperTeam View All Drug Pricing Experts
